ResMed (NYSE:RMD) Price Target Cut to $215.00 by Analysts at Wells Fargo & Company

ResMed (NYSE:RMD) had its price objective cut by Wells Fargo & Company from $225.00 to $215.00 in a research note issued to investors on Friday morning,Benzinga reports. They currently have an equal weight rating on the medical equipment provider’s stock.

Several other brokerages have also recently weighed in on RMD. Weiss Ratings cut shares of ResMed from a “hold (c)” rating to a “hold (c-)” rating in a research report on Friday, July 24th. Mizuho reduced their target price on shares of ResMed from $235.00 to $220.00 and set an “outperform” rating on the stock in a research note on Wednesday, July 15th. Royal Bank Of Canada lowered shares of ResMed from an “outperform” rating to a “sector perform” rating and set a $234.00 target price on the stock. in a report on Thursday, July 16th. JPMorgan Chase & Co. started coverage on shares of ResMed in a research note on Wednesday, April 15th. They issued an “overweight” rating for the company. Finally, UBS Group restated a “buy” rating and set a $300.00 price target on shares of ResMed in a report on Tuesday, July 21st. Seven investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $240.17.

ResMed Price Performance

NYSE:RMD opened at $211.84 on Friday. ResMed has a one year low of $180.26 and a one year high of $293.81. The stock has a market cap of $30.73 billion, a PE ratio of 20.31, a P/E/G ratio of 1.36 and a beta of 0.76. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.33 and a current ratio of 3.01. The stock has a 50 day moving average price of $200.49 and a 200 day moving average price of $222.23.

ResMed (NYSE:RMD) last issued its earnings results on Thursday, August 6th. The medical equipment provider reported $2.95 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.89 by $0.06. ResMed had a return on equity of 25.86% and a net margin of 26.94%.The company had revenue of $1.46 billion during the quarter, compared to analysts’ expectations of $1.46 billion. During the same period in the prior year, the business earned $2.55 EPS. The firm’s quarterly revenue was up 8.6% on a year-over-year basis. Equities research analysts expect that ResMed will post 12.02 EPS for the current fiscal year.

ResMed Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 24th. Stockholders of record on Thursday, August 20th will be paid a $0.66 dividend. The ex-dividend date of this dividend is Thursday, August 20th. This is a boost from ResMed’s previous quarterly dividend of $0.60. This represents a $2.64 dividend on an annualized basis and a dividend yield of 1.2%. ResMed’s payout ratio is presently 23.14%.

Insider Buying and Selling at ResMed

In other ResMed news, Director Peter C. Farrell sold 8,000 shares of ResMed stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $225.00, for a total value of $1,800,000.00. Following the completion of the transaction, the director directly owned 52,773 shares of the company’s stock, valued at $11,873,925. The trade was a 13.16% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Michael J. Farrell sold 4,991 shares of the business’s stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $218.55, for a total transaction of $1,090,783.05. Following the sale, the chief executive officer owned 466,223 shares in the company, valued at $101,893,036.65. This trade represents a 1.06% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 17,982 shares of company stock worth $3,858,837 in the last quarter. Company insiders own 0.65% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. International Assets Investment Management LLC purchased a new stake in ResMed during the 4th quarter worth approximately $25,000. Bell Investment Advisors Inc purchased a new position in ResMed in the 2nd quarter valued at approximately $26,000. Imprint Wealth LLC purchased a new position in ResMed in the 3rd quarter valued at approximately $26,000. WFA of San Diego LLC purchased a new position in ResMed in the 2nd quarter valued at approximately $26,000. Finally, Sunbelt Securities Inc. acquired a new position in shares of ResMed in the third quarter worth $31,000. Hedge funds and other institutional investors own 54.98% of the company’s stock.

Trending Headlines about ResMed

Here are the key news stories impacting ResMed this week:

• Positive Sentiment: ResMed reported fiscal Q4 earnings of $2.95 per share, beating the approximately $2.89–$2.90 consensus and rising from $2.55 a year earlier. Revenue increased 8.6% year over year to $1.46 billion, in line with estimates. ResMed Q4 Earnings and Revenues Top Estimates
• Positive Sentiment: The company raised its quarterly dividend from $0.60 to $0.66 per share, a 10% increase. The dividend is payable September 24 to shareholders of record on August 20, supporting ResMed’s income-investment appeal. ResMed Posts Strong Q4 Earnings and Lifts Dividend
• Positive Sentiment: Royal Bank of Canada raised its price target to $244 from $234 while retaining a “sector perform” rating, indicating potential upside from recent trading levels. Benzinga analyst action
• Neutral Sentiment: Analyst sentiment remains mixed. Piper Sandler lowered its target to $225 and Wells Fargo cut its target to $215; both maintain neutral or equal-weight ratings. The overall analyst consensus remains “Hold,” despite a consensus target near $246. ResMed Analyst Ratings
• Negative Sentiment: The primary pressure on RMD is forward guidance: fiscal 2027 revenue expectations reportedly trail consensus, raising concerns that growth may moderate even after the quarterly earnings beat. RMD Stock Down Despite Q4 Earnings Beat
• Negative Sentiment: Director Peter Farrell sold 8,000 shares worth $1.8 million. The sale was made under a pre-arranged Rule 10b5-1 plan, reducing its negative signaling value, but it may add modest short-term selling pressure. SEC Insider Trading Filing

ResMed Company Profile

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.